Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
US12084483B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Aug 5, 2015 |
| Grant date | Sep 10, 2024 |
| Priority date | — |
| Expiry date | Jan 10, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/21
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Various methods and compositions are provided which can be employed to modulate the immune system. Compositions include a fusion protein comprising: (a) a first polypeptide comprising Interleukin-2 (IL-2) or a functional variant or fragment thereof; and (b) a second polypeptide, fused in frame to the first polypeptide, wherein the second polypeptide comprises an extracellular domain of Interleukin-2 Receptor alpha (IL-2Rα) or a functional variant or fragment thereof, and wherein the fusion protein has IL-2 activity. Various methods are provided for modulating the immune response in a subject comprising administering to a subject in need thereof a therapeutically effective amount of the IL-2/IL-2Rα fusion protein disclosed herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.